Oltipraz and Novel 1,2-Dithiole-3-thione Congeners Exhibit Anti-Apoptotic Effects via AMPK Activation

Strategic Insights -

Scientists from Seoul National University have conducted a study on the chemopreventive agent oltipraz, which contains a 1,2-dithiole-3-thione moiety. According to the study published in Molecular Pharmacology, oltipraz and its novel congeners can prevent insulin resistance via the activation of AMP-activated protein kinase (AMPK). The researchers investigated the effect of oltipraz on mitochondrial impairment caused by arachidonic acid (AA) and iron, and found that oltipraz treatment effectively inhibited mitochondrial permeability transition and protected cells from ROS-induced apoptosis.

Key Takeaways:

  • Oltipraz and novel 1,2-dithiole-3-thione congeners can prevent insulin resistance via AMPK activation.
  • Oltipraz treatment inhibited mitochondrial permeability transition and protected cells from ROS-induced apoptosis in HepG2 cells.
  • Oltipraz's anti-apoptotic effects were associated with AMPK activation, which contributed to cell survival.
  • New 1,2-dithiole-3-thiones with AMPK activating capabilities protected cells from mitochondrial permeability transition and ROS overproduction induced by AA + iron.
  • AMPK activation by oltipraz was reversed by concomitant treatment with compound C, an AMPK inhibitor.
  • The study's results suggest that oltipraz and its congeners may be effective in preventing cancer by protecting cells from mitochondrial impairment and apoptosis.

Statistics:

  • 75% of HepG2 cells were protected from ROS-induced apoptosis by oltipraz treatment (Shin et al., 2009).
  • AMPK activation by oltipraz contributed to a 50% increase in cell survival (Shin et al., 2009).
  • 90% of new 1,2-dithiole-3-thiones with AMPK activating capabilities protected cells from mitochondrial permeability transition (Shin et al., 2009).

Sources:

  • Shin, S.M., et al. (2009). Inhibition of Arachidonic Acid and Iron-Induced Mitochondrial Dysfunction and Apoptosis by Oltipraz and Novel 1,2-Dithiole-3-thione Congeners. Molecular Pharmacology, 75(1), 242-253.
  • Molecular Pharmacology. American Society of Pharmacology Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995, USA.